Live news related to CELLECTIS stock (FR0010425595): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Cellectis has announced encouraging results from phase 1 of the BALLI-01 clinical trial for lasmé-cel, targeting patients with relapsed or refractory …
The biotechnology company's stock ended the week at €3.60, up from €2.995 on Monday, marking a 20.2% increase over five trading days. This surge stark…
